The UK and US have forged a key bilateral deal that will keep zero import taxes on UK medicine products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the NHS. This commitment ensures that duties on these vital products will stay at zero for a period of the next three years.
This agreement follows earlier warnings to hike duties on patented drug imports, with figures mentioned up to one hundred percent.
"This arrangement between the Britain bolsters the worldwide climate for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," a statement declared.
Economic Importance
Drugs constitute one of the UK's largest exports to the US, which is easily the primary buyer for large UK drugmakers.
Trade data show that in the 12 months prior to the third quarter, the UK exported medicines totaling £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that timeframe.
"This deal safeguards work, stimulates investment and sets the stage for the UK to become a international leader for life sciences," a government official commented.
Key NHS Changes
The agreement involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise total public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be restricted at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The pact follows a ongoing row between the drug companies and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by assertions that American customers were charged a premium for the identical medicines than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or scrapped, while major expansions have been pledged toward US facilities.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
